# Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference

> **NIH NIH R13** · FRED HUTCHINSON CANCER CENTER · 2024 · $74,999

## Abstract

PROJECT SUMMARY
ANNUAL TRANSLATIONAL HIV EARLY STAGE INVESTIGATOR (ESI) CONFERENCE
This R13 application requests continued NIH support for four annual conferences for Early Stage Investigators
(ESIs) conducting translational HIV vaccine, cure, immunology, and co-infection research with non-human
primates (NHPs). These meetings are organized contiguous with the NHP AIDS Symposium and gather ESIs
and mentors for scientific networking, career development, and training in translational science skills. In Year
1, the meeting will be held at the Tulane National Primate Center in New Orleans, LA in conjunction with the
NHP AIDS Symposium. The conferences are planned by a diverse advisory group of experts in the field
including scientists at all stages of their careers. K01 HIV/AIDS Scholars and mentors complete a needs
assessment to determine priority topics for the meeting. The advisory committee develops the meeting agenda
using the input from this needs assessment. Attendees at the ESI Conferences will participate in training and
skill-building activities on important translational scientific topics (e.g., cure, prevention, vaccine, and
therapeutic research; NHP models of TB and coinfections); mentoring opportunities with senior and peer
investigators (e.g., panel discussions on career development); skill building for research career development
training (e.g., ESI funding landscape, how to conduct research with HIV Vaccine Trials Network (HVTN),
manuscript writing); “Works in Progress” presentations; and organized networking opportunities with other ESIs
and senior investigators (e.g., receptions, speed dating, and small group discussions). The meeting has no
registration fee and travel scholarships will be awarded to talented ESIs, with priority for underrepresented
applicants, and K01 Scholars and mentors, thus providing opportunities for these groups to continue to interact
and support translational science. The inclusion of women, underrepresented minorities and individuals with
disabilities will be supported as speakers, attendees, and advisors, with a goal of creating a meeting
environment that is welcoming to diverse scientists. HVTN staff will organize the conference and will provide
further translational research opportunities by facilitating participation for 3 K01 Scholars at the annual HVTN
Full Group Meeting in Washington, DC. These conferences will fill a critical gap in scientific knowledge and
workforce development by ensuring that the next generation of diverse ESI are able to facilitate greater
translation of research between preclinical NHP studies and clinical trials. Building a workforce for the future
composed of scientists with strong translational skills is critical to ending the HIV epidemic and developing HIV
vaccines, therapeutics, and cure strategies.

## Key facts

- **NIH application ID:** 10835683
- **Project number:** 2R13OD024033-08
- **Recipient organization:** FRED HUTCHINSON CANCER CENTER
- **Principal Investigator:** James G. Kublin
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $74,999
- **Award type:** 2
- **Project period:** 2017-04-07 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10835683

## Citation

> US National Institutes of Health, RePORTER application 10835683, Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference (2R13OD024033-08). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10835683. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*